© Copyright Acquisition International 2026 - All Rights Reserved.

Article Image - At the Heart of Europe’s Cardiovascular Research Scene
Posted 6th February 2024

At the Heart of Europe’s Cardiovascular Research Scene

Founded in 2012, the European Cardiovascular Research Institute (ECRI) was established for the purposes of serving as a collaborative effort for European nations to undertake investigator-initiated cardiology studies.

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

At the Heart of Europe’s Cardiovascular Research Scene
Technology to analyze medical data and predict risk

Founded in 2012, the European Cardiovascular Research Institute (ECRI) was established for the purposes of serving as a collaborative effort for European nations to undertake investigator-initiated cardiology studies. Cardiology Research Organisation of the Year 2023 – Europe awardee ECRI today facilitates both the design and execution of such studies and trials, with each proudly boasting full certification and adherence to ICH, GCP, and ISO standards and guidelines. At present, randomised trials are being carried out whereby ECRI is the sponsor, with these being possible thanks to scientific grants generously afforded by those in leading industry positions. Thanks to this groundbreaking initiative carried out with the support of industry leaders boasting expertise in their respective fields, a multicentre, multinational experience has been created that possesses endless opportunities for study and development in the realm of cardiovascular health.

As a non-profit institute that proudly brings together Europe’s top clinical researchers and supporting industry staff to carry out clinical studies aiming to demonstrably improve cardiovascular healthcare, the European Cardiovascular Research Institute nobly manages and implements such studies in line with international regulations and to a series of pre-established budgets and timelines. These efforts are rooted primarily in collaboration with experts from across Europe, which is where a considerable amount of its investigation sites are located, and trials carried out. The exception to the rule is the Global Leaders and Master Dapt studies, with these having sites across a multitude of continents in addition to Europe.

One clearly apparent strength of this united front is that it assembles a large network of both investigators and sites, serving to provide the ECRI with the unique advantage of being able to select a site quickly from one of its nearly 40 partner countries, with the large scale of this operation also offering a large pool of possible patients, enabling enrolments to be undertaken in a swift yet realistic manner. By involving pioneers in the field of cardiology from a host of countries, resources can be combined, and project managers sourced that are able to offer unique insight, something that is particularly effective when it comes to assessing the quality of the available clinical data and images.

Regarding the countries which presently enrol patients into ECRI studies, the list is expansive and spans multiple continents, highlighting how regions all over the world can come together effectively to work towards groundbreaking research on such a vital area of study. These countries are, Austria, Argentina, Australia, Bangladesh, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Denmark, Estonia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Kazakhstan, Kingdom of Bahrain, Luxembourg, Macedonia, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, UK, and Vietnam.

Across these 38 countries is almost a dozen representative experts who make up ECRI’s Scientific Advisory Board, with this esteemed group consisting of a series of like-minded scientists, cardiologists, and statisticians, each of whom has demonstrated a keen interest in pursuing the designing and execution of these clinical trials. In an effort to co-design and stimulate clinical investigations on a trans-Atlantic level, this board is inclusive of trialists from across Europe and faculty from other continents across the globe, and membership is pro bono and can be secured by invitation only.

Each and every project undertaken by the ECRI is also managed by a steering committee, with this distinguished group of individuals being comprised of true scientific and clinical leaders. An ECRI representative is too always on hand, ensuring that things run smoothly. Further solidifying the safety of all operations is a series of independent data and safety monitoring boards, as well as clinical events committees, with these groups present to guarantee patient safety, data integrity, and the assessment of outcomes are all upheld to the highest calibre.

Located at the very heart of ECRI is a desire to serve as a pioneer in the realm of trial leadership, with this being achieved through supporting industry, the sites, and subcontractors that in turn support it. Since it is a non-profit organisation, ECRI offers sponsorship capabilities inclusive of contracting and subcontracting, patient insurance, quality assurance, risk management, project oversight, and controlling budgets. This is incredibly important in today’s environment, as there is less funding available for clinical research, and the plethora of requirements that have to be fulfilled before a trial can be carried out have resulted in single companies finding it increasingly difficult to raise the necessary funds for their studies.

It is this environment that ultimately produced ECRI, with this institute being founded for the purposes of serving as an intermediary between academic leaders and the supporting industry vital in funding such endeavours. The successful relationships that have been forged are clear to see, and in the past decade or so, 12 studies have been carried out, with a particularly notable trial being named “Global Leaders” and consisting of 16,000 “all-comer” patients who were enrolled in 130 centres and hospitals across 18 countries in Europe, Australia, Brazil, Canada, and Singapore.

This study saw patients being treated with the drug bivalirudin (in the countries where it is available) and a biomatrix stent, which had been fully randomised to produce either ticagrelor and aspirin followed by one month of ticagrelor monotherapy for a course of 23 months, or an intensive dual antiplatelet therapy, with this course of treatment lasting for 24 months. The first patient in this trial was enrolled by Belgium’s Dr Aminian from the CHU in Charleroi, and the whole trial was operated under ECRI’s umbrella, and supported by grants from businesses such as Biosensors, AstraZeneca, and The Medicines Company.

Across this incredibly important trial, partner company Cardialysis was made responsible for carrying out project and data management, site monitoring, safety reporting, and carrying out ECG analysis, among other such tasks. Results from this trial were published in The Lancet in 2018, with the primary endpoint concluding that, “experimental treatment strategy [is] superior to reference treatment strategy on cumulative 2-year composite of all cause mortality and new Q-wave MI.” These results serve as just one example of the stellar work that has been carried out over the last decade, with exceptional results sure to continue well into the future with the host of cardiovascular clinical trials currently underway.

Quintessentially, the trials that have been carried out by the European Cardiovascular Research Institute have immeasurably benefited the lives of countless people across Europe and even further afield, and with more than 400 people dying from heart and circulatory diseases every day in the UK, these efforts are more important now than ever before, with these numbers only set to increase. As a result of the phenomenal work done by the European Cardiovascular Research Institute, it is our pleasure to provide it with this award, and we wish the team all the best in all of their future trials and studies.

For business enquiries, contact Ernest Spitzer from European Cardiovascular Research Institute on their website – https://www.ecri-trials.com/

Ernest Spitzer

Categories: Corporate Social Responsibility, News


You Might Also Like
Read Full PostRead - Eye Icon
The Legal Implications of Co-Owning a Family Business
Legal
01/02/2023The Legal Implications of Co-Owning a Family Business

Frequently, owners and shareholders of family firms can balance their professional and personal obligations. It could be challenging to maintain peace and advance as a civilization simultaneously.

Read Full PostRead - Eye Icon
Unlock Proven Investment Strategies With Kavan Choksi
News
28/04/2023Unlock Proven Investment Strategies With Kavan Choksi

Are you looking to get ahead financially in the coming year? With so much economic and political uncertainty, how can you ensure that your investments are sound and strategic?

Read Full PostRead - Eye Icon
The Hidden Cost of Overuse and Misuse of Data Storage
News
06/08/2025The Hidden Cost of Overuse and Misuse of Data Storage

Most organisations are storing far more data than they use, and while keeping it “just in case” might feel like the safe option, it’s a habit that can quietly chip away at budgets, performance, and even sustainability goals.

Read Full PostRead - Eye Icon
The Importance of IP in M&A transactions
Innovation
19/11/2015The Importance of IP in M&A transactions

For the past 10 years, Coller IP has been at the forefront of developments in Intangible Asset Management. Jackie Maguire profiles the firm and explains their place in the market.

Read Full PostRead - Eye Icon
What to Do if You Can’t Make Your Business Loan
News
02/12/2021What to Do if You Can’t Make Your Business Loan

What To Do If You Can’t Make Your Business Loan There are a lot of moving parts to make a loan from your business. You have to meet all of these requirements and you need to do it fast. But not every company manages to obtain a business loan, even if the

Read Full PostRead - Eye Icon
IT Consulting 101: How It Works and Why Your Business Needs It
News
04/11/2021IT Consulting 101: How It Works and Why Your Business Needs It

Any business that wants to remain relevant and competitive must utilize information technology (IT). IT involves the use of modern tools and applications to promote business efficiency.

Read Full PostRead - Eye Icon
Seven Easy Steps Employers Can Take to Engage Gen Z in the Workplace
Leadership
01/07/2024Seven Easy Steps Employers Can Take to Engage Gen Z in the Workplace

Whether it is maintaining flexibility in the workplace or scrapping annual reviews, there are plenty of ways to keep this generation engaged. Below you can find compelling insights into how Gen Z is navigating the workplace, and effective strategies emplo

Read Full PostRead - Eye Icon
How Executive Hiring Is Changing in the Age of AI
Leadership
10/08/2026How Executive Hiring Is Changing in the Age of AI

How Executive Hiring Is Changing in the Age of AI Senior roles are no longer advertised in the same way, and as a result, senior candidates are facing a whole new landscape. The early stages of an Executive Search are increasingly influenced by AI. Furthermore

Read Full PostRead - Eye Icon
Unlocking Hidden Value in Privately-Held Acquisition Targets
Finance
20/10/2025Unlocking Hidden Value in Privately-Held Acquisition Targets

In private company acquisitions, hidden value refers to the unrealized potential that isn’t reflected on financial statements but can significantly impact long-term performance.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow